News from oxford biotherapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

21 Dec, 2018, 13:54 GMT Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076

An experimental first in class ADC medicine for high risk Her2 negative breast cancer, gastric, lung, bladder and ovarian cancer patients - US phase...


01 Mar, 2018, 10:00 GMT Oxford BioTherapeutics Appoints Chief Medical Officer, Abderrahim Fandi M.D., Ph.D.

Oxford BioTherapeutics ("OBT"), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate based therapies,...


13 Jun, 2017, 08:00 BST Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate based therapies, has...


09 Feb, 2017, 08:00 GMT Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans

Oxford BioTherapeutics ("OBT"), an international biotechnology company developing clinical stage antibody therapeutics for cancer, today announced a...


18 Apr, 2016, 08:00 BST Boehringer Ingelheim Exercises Option on Second Oncology Target Using Oxford BioTherapeutics' OGAP® System

Oxford BioTherapeutics, a biotechnology company focused on developing innovative antibody therapeutics to treat cancer, today announces that...


04 Apr, 2016, 09:23 BST Oxford BioTherapeutics Licenses Nerviano Medical Sciences' Drug-Linker Technology to Develop Novel Antibody Drug Conjugates

Oxford BioTherapeutics (OBT), a company developing a range of innovative Antibody Drug Conjugates (ADCs) for the treatment of cancer and Nerviano...


25 Nov, 2014, 11:00 GMT $1 Billion Oncology Alliance between Menarini Group & Oxford BioTherapeutics Initiates First-in-Human Study of Enhanced Antibody for Treatment of Acute Myeloid Leukemia

Oxford BioTherapeutics and Berlin Chemie/ Menarini Biotech/ Menarini Ricerche (belonging to Menarini Group) announce today that they have initiated...


02 Oct, 2014, 11:48 BST Oxford BioTherapeutics and Berlin-Chemie/Menarini Group Progress Antibody-Drug Conjugate as Second Clinical Development Candidate in $1 Billion Oncology Investment Alliance

Oxford BioTherapeutics (OBT) and Berlin Chemie/Menarini Group announce today that they have designated a novel antibody-drug conjugate (ADC)...


15 Jan, 2014, 14:00 GMT Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors

Oxford BioTherapeutics, an international biotechnology company developing antibody-drug conjugates for cancer, today announced the appointment of...


09 Dec, 2013, 12:11 GMT Oxford BioTherapeutics and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia as First Clinical Development Candidate in $1 Billion Oncology Investment Alliance

Oxford BioTherapeutics (OBT) and Berlin-Chemie (Menarini Group) announce today that they have designated a novel enhanced antibody targeting acute...


26 Jun, 2013, 12:07 BST Oxford BioTherapeutics Appoints Bryan G. Morton as Chairman

Oxford BioTherapeutics (OBT), a global biotechnology company developing first-in-class, antibody-based cancer medicines to fulfil unmet patient...


29 Apr, 2013, 09:00 BST Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer

Oxford BioTherapeutics (OBT) and Boehringer Ingelheim (BI) today announce a new alliance focused on the discovery of novel cancer antibody targets...


02 May, 2012, 10:58 BST Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland

Oxford BioTherapeutics (OBT) today announces the appointment of Dr Esteban Pombo-Villar as Chief Operations Officer (COO) of the OBT group. In this...


11 Jan, 2012, 16:18 GMT Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director

Oxford BioTherapeutics (OBT) today announces that it has appointed C. Glenn Begley as a senior clinical advisor and non-executive director. Dr...


06 Apr, 2011, 11:00 BST Oxford BioTherapeutics Licenses BioWa's POTELLIGENT(R) Technology for the Research and Development of its Therapeutic Antibodies in Cancer

BioWa, Inc. (BioWa) and Oxford BioTherapeutics Ltd (OBT) today announced that they have entered into a license agreement to provide OBT with access...